Leaving Medicine to Fix the System: Lessons from a Serial Founder

The transition from practitioner to entrepreneur requires a fundamental shift in perspective. Early in his career, O’Leary founded NeoGenomics Laboratories during the initial wave of genomic sequencing. He discovered that while scientific breakthroughs are essential, they are insufficient on their own. Success in entrenched industries requires navigating the long, often painful distance between technological possibility and actual market adoption.

O’Leary argues that founders frequently err by building for intermediaries—the administrators and payers who control budgets—rather than the end users. In healthcare, this often exacerbates existing inefficiencies. Instead, he advocates for solutions that simplify the patient journey, emphasizing that trust serves as a more durable competitive advantage than technical features. By prioritizing distribution and engagement over pure product development, companies can integrate into the complex workflows that traditionally resist disruption.

Looking ahead, O’Leary identifies artificial intelligence as the primary tool to achieve the scale his father once provided to a single small town. By fragmenting data silos and guiding patients through the system, AI offers a path toward predictive, coordinated care. His current work at HealthLynked focuses on this shift, aiming to empower patients to own their medical data. For those looking to disrupt legacy sectors, the lesson remains consistent: the most significant opportunities lie where the infrastructure is still catching up to the science, requiring founders to operate with long-term conviction before the market reaches a consensus.